Development and evaluation of murine lung-specific disease models for Pseudomonas aeruginosa applicable to therapeutic testing

Pathogens and Disease

Volumn 73, Issue 5, 2015, Pages

  Lawrenz, Matthew B ^a   Biller, Ashley E ^a   Cramer, Daniel E ^a   Kraenzle, Jennifer L ^a   Sotsky, Julie B ^a   Vanover, Carol D ^a   Yoder Himes, Deborah R ^b   Pollard, Angela ^c   Warawa, Jonathan M ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c AGILE SCIENCES   (United States)

Author keywords

Biometric endpoint criteria; Intubation mediated intratracheal (IMIT) inoculation; MDR Pseudomonas aeruginosa; Murine respiratory disease; Therapeutic model

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBAPENEM; MEROPENEM; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL PNEUMONIA; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LD50; LEUKOPENIA; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; ANIMAL; BAGG ALBINO MOUSE; BIOMETRY; DISEASE MODEL; DRUG EFFECTS; EVALUATION STUDY; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGY; PATHOLOGY; PNEUMONIA, BACTERIAL; PRECLINICAL STUDY; PROCEDURES; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOMETRY; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; LETHAL DOSE 50; MICE, INBRED BALB C; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; THIENAMYCINS; TREATMENT OUTCOME;

EID: 85001875278     PISSN: None     EISSN: 2049632X     Source Type: Journal    
DOI: 10.1093/femspd/ftv025     Document Type: Article

References (21)

1. Abdi-Ali A, Mohammadi-Mehr M, Agha Alaei Y. Bactericidal activity of various antibiotics against biofilm-producing Pseudomonas aeruginosa. Int J Antimicrob Ag 2006;27:196-200.
2. Biswal I, Arora BS, Kasana D, et al. Incidence of multidrug resistant Pseudomonas aeruginosa isolated from burn patients and environment of teaching institution. J Clin Diagn Res 2014;8:DC26-9.
3. Bonifacio SL, Kitterman JA, Ursell PC. (2003), Pseudomonas pneumonia in infants: an autopsy study. Hum Pathol 2003;34:929-38.
4. Carmeli Y, Troillet N, Eliopoulos GM, et al. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Ch 1999;43:1379-82.
5. Center for Drug Evaluation and Research (CDER). Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. Rockville, MD: Food and Drug Administration, 2005.
6. Dantas G, Sommer MO, Oluwasegun RD, et al. Bacteria subsisting on antibiotics. Science 2008;320:100-3.
7. Gambello MJ, Iglewski BH. Cloning and characterization of the Pseudomonas aeruginosa lasR gene, a transcriptional activator of elastase expression. J Bacteriol 1991;173:3000-9.
8. Jesaitis AJ, Franklin MJ, Berglund D, et al. Compromised host defense on Pseudomonas aeruginosa biofilms: characterization of neutrophil and biofilm interactions. J Immunol 2003;171:4329-39.
9. LawrenzMB, Fodah RA, Gutierrez MG, et al. Intubation-mediated intratracheal (IMIT) instillation: a noninvasive, lung-specific delivery system. J Visualized Exp 2014;17:e52261.
10. Louie A, Liu W, Fikes S, et al. Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia. Antimicrob Agents Ch 2013;57:2788-92.
11. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. M100-S24.Wayne, PA: Clinical Laboratory Standards Institute, 2014.
12. Ochsner UA, Koch AK, Fiechter A, et al. Isolation and characterization of a regulatory gene affecting rhamnolipid biosurfactant synthesis in Pseudomonas aeruginosa. J Bacteriol 1994;176:2044-54.
13. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. Fed Am Soc Exp Biol J 2008;22:659-61.
14. Sader HS, Farrell DJ, Flamm RK, et al. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). Diagn Micr Infec Dis 2014;78: 443-8.
15. Scarff JM, Goldberg JB. Vaccination against Pseudomonas aeruginosa pneumonia in immunocompromised mice. Clin Vaccine Immunol 2008;15:367-75.
16. Shaver CM, Hauser AR. Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung. Infect Immun 2004;72:6969-77.
17. Stover CK, Pham XQ, Erwin AL, et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 2000;406:959-64.
18. Tam VH, Rogers CA, Chang KT, et al. Impact of multidrugresistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Ch 2010;54:3717-22.
19. Tseng BS, Zhang W, Harrison JJ, et al. The extracellular matrix protects Pseudomonas aeruginosa biofilms by limiting the penetration of tobramycin. Environ Microbiol 2013;15: 2865-78.
20. Wei Q, Tarighi S, Dõtsch A, et al. Phenotypic and genome-wide analysis of an antibiotic-resistant small colony variant (SCV) of Pseudomonas aeruginosa. PLoS ONE 2011;6:e29276.
21. Yahr TL, Vallis AJ, Hancock MK, et al. ExoY, an adenylate cyclase secreted by the Pseudomonas aeruginosa type III system. P Natl Acad Sci USA 1998;95:13899-904.